VSTM halted on Oct 14 2026 at $7.87
VSTM+5.6%on Wed Oct 14 2026
Verastem, Inc. was up 5.6% on the day at $7.87, ranked #80 on 33.8× its usual five-minute volume, when TapeRank recorded this trading halt at 09:43 ET during regular hours when it was halted. TapeRank recorded 3 events for VSTM that day, between 06:05 and 09:43 ET, and each is in the timeline below.
THE DAY ON THE LIST · 3 EVENTS
- 06:05 ETUNEXPLAINED MOVE · PRE-MARKET
$8.67 · ▲ 16.4% ON THE DAY · 122× 5M RVOL · RANK #1
UNEXPLAINEDNO FILINGS · RULEVSTM is up 1.5% on the day on 12.1x its normal volume for this time of day. No filings or headlines were found in SEC EDGAR filings and Benzinga wire headlines in the last 24 hours, so this is order flow rather than a disclosed catalyst.
WHYNo filings or headlines within 24 hours of the move.ANALYZED 06:01 ET · 4 MIN AGO · RULE, NO MODELTHE ROW AND SESSION LEVELS AT 06:05 ET
LAST8.67DAY▲ 16.4%5 MIN▲ 16.85%5M RVOL122×5M $VOL$376KFLOAT*90.6MRANK#1SESSIONPRE-MARKETVWAP7.72HOD8.42LOD7.09OR HIGH—OR LOW—PREV CLOSE7.45PM HIGH8.42PM LOW7.09GAP▲ 7.38% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
- 06:12 ETMOVER · PRE-MARKET
$9.15 · ▲ 22.8% ON THE DAY · 562× 5M RVOL · RANK #8
JUSTIFIEDCONFIDENCE5/5VSTM is up 16.5% pre-market after reporting strong early VS-7375 clinical activity, including a 41% confirmed response rate in second-line-or-later pancreatic cancer, alongside improved preliminary revenue. The move is supported by meaningful clinical data, but a priced $247.5 million offering of 30.94 million shares creates substantial dilution into the strength.
WHYA 16.5% move is broadly proportionate to positive multi-tumor Phase 1/2 data and sharply higher revenue, though the offering offsets part of the upside and adds 34% to the 90.6M share float proxy.ANALYZED 06:11 ET · <1 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 06:12 ET
LAST9.15DAY▲ 22.8%5 MIN▲ 4.10%5M RVOL562×5M $VOL$2.1MFLOAT*90.6MRANK#8SESSIONPRE-MARKETVWAP8.45HOD9.00LOD7.09OR HIGH—OR LOW—PREV CLOSE7.45PM HIGH9.00PM LOW7.09GAP▲ 17.45% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
- 09:43 ETHALT · REGULAR
HALTED AT $7.87 · ▲ 5.6% ON THE DAY · 33.8× 5M RVOL · RANK #80
No verdict was committed for this event.
THE ROW AND SESSION LEVELS AT 09:43 ET
LAST7.87DAY▲ 5.6%5 MIN▲ 7.81%5M RVOL33.8×5M $VOL$3.8MFLOAT*90.6MRANK#80SESSIONREGULARVWAP7.85HOD9.24LOD6.70OR HIGH8.05OR LOW7.73PREV CLOSE7.45PM HIGH9.24PM LOW7.09GAP▲ 7.38%* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
NO VERDICT MEANS THE MODEL HAD NOT REACHED THE NAME BEFORE THE EVENT WAS FINALIZED, OR ITS ANSWER HEDGED AND WAS WITHHELD. NOTHING WAS FILLED IN AFTERWARDS.
THE SESSION
- 09:30 ETOpened at $8.00, +7.4% on the previous close of $7.45
- 09:37 ETRegular-session low, $6.70
- 09:42 ETHalted (LUDP); resumed 09:47 ET, after 5 minutes
- 11:12 ETRegular-session high, $8.96
- 15:59 ETLast trade of the regular session, $7.71, +3.5% on the previous close of $7.45
- Volume: 28.5M shares in regular hours, 4.7M before the open
VSTM opened at $8.00 after TapeRank tied the premarket move to positive VS-7375 clinical data, including a 41% confirmed response rate in later-line pancreatic cancer, alongside improved preliminary revenue; the priced $247.5 million share offering tempered that read. The stock fell to $6.70 by 09:37, halted at 09:42 for five minutes, then recovered to a session high of $8.96 at 11:12 before ending at $7.71, still above the previous close. TapeRank recorded no additional filing or headline explaining the later reversal.
WRITTEN THU OCT 15 2026 18:05 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
- 06:10 ETVerastem Oncology Priced Underwritten Offering Of 30.94M Common Shares At $8.00 Per Share For $247.5M In Gross ProceedsBenzinga
- 06:08 ET8-K — Results of Operations and Financial Condition; Departure or Election of Directors or Officers; Regulation FD Disclosure; Other Events; Financial Statements and ExhibitsSEC 8-K
- 06:07 ETVerastem Oncology Appoints Michael P. Bailey As President And CEO, Effective January 1, 2027Benzinga
- 06:05 ETVerastem Oncology Announces Initial Data In First Multi-Tumor Update From Ongoing TARGET-D 101 Phase 1/2 Clinical Trial Evaluating VS-7375; Data Demonstrate Robust Clinical Activity With Favorable Safety And Tolerability Profile Across Multiple Dose Levels And Tumor TypesBenzinga
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list